Dataset Information


Hartmann2016 - Blood coagulation model for simulating anticoagulants

ABSTRACT: Mathematical model of blood coagulation. Reused Wajima2009 model with modifications to reactions 27 (formation of Va:Xa complex), 32 (Xa inhibition by TFPI) and 45 (Xa inhibition by TFPI-Heparin complex) as described in publication equations 2,3 and 4. Publication lists parameter sets to simulate Rivaroxaban, VKA and Enoxaparin (supplementary files).

SUBMITTER: Matthew Roberts  

PROVIDER: MODEL1807180004 | BioModels | 2018-07-18


Dataset's files

Action DRS
MODEL1807180004?filename=Hartmann2016.cps Other
MODEL1807180004?filename=Hartmann2016.xml Xml
Items per page:
1 - 2 of 2
altmetric image


Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.

Hartmann S S   Biliouris K K   Lesko L J LJ   Nowak-Göttl U U   Trame M N MN  

CPT: pharmacometrics & systems pharmacology 20160920 10

Warfarin is the anticoagulant of choice for venous thromboembolism (VTE) treatment, although its suppression of the endogenous clot-dissolution complex APC:PS may ultimately lead to longer time-to-clot dissolution profiles, resulting in increased risk of re-thrombosis. This detrimental effect might not occur during VTE treatment using other anticoagulants, such as rivaroxaban or enoxaparin, given their different mechanisms of action within the coagulation network. A quantitative systems pharmaco  ...[more]

Similar Datasets

1997-01-01 | S-EPMC1218311 | BioStudies
2014-01-01 | S-EPMC4030531 | BioStudies
2017-01-01 | S-EPMC5745139 | BioStudies
2018-06-07 | MODEL1806070001 | BioModels
2012-01-01 | S-EPMC3692300 | BioStudies
2002-01-01 | S-EPMC1222898 | BioStudies
1000-01-01 | S-EPMC43575 | BioStudies
2018-01-01 | S-EPMC5880031 | BioStudies
2013-01-01 | S-EPMC3796881 | BioStudies
2008-01-01 | S-EPMC2517609 | BioStudies